Toward rational fragment-based lead design without 3D structures.

Area of Science:

• Drug discovery and medicinal chemistry
• Structural biology
• Biophysics

Background:

• Fragment-based lead discovery (FBLD) is crucial for identifying low molecular weight ligands for drug targets.
• High-resolution structural information (X-ray crystallography, NMR) is typically required for FBLD, posing a bottleneck.
• Existing FBLD methods rely heavily on the availability of 3D structural data of target-ligand complexes.

Purpose of the Study:

• To present an alternative strategy for rational lead identification when 3D structural data is unavailable.
• To demonstrate the utility of the meta-structure approach in fragment-based drug design.
• To show how NMR data can be integrated with the meta-structure approach for lead optimization.

Main Methods:

• Utilizing the meta-structure approach for identifying potential binding sites without 3D structural information.
• Employing Nuclear Magnetic Resonance (NMR) spectroscopy to gather information-rich data on fragment binding.
• Combining meta-structure insights with NMR data to guide fragment evolution and lead development.

Main Results:

• The meta-structure approach provides a viable alternative for rational lead identification in the absence of 3D structures.
• The integration of NMR data with the meta-structure strategy yields valuable insights for fragment development.
• Demonstrated feasibility of this combined approach through several examples, enabling fragment evolution without high-resolution protein structures.

Conclusions:

• The combined NMR and meta-structure approach offers a powerful strategy to overcome structural data limitations in FBLD.
• This method facilitates rational lead identification and optimization, expanding the scope of fragment-based drug design.
• The presented approach provides a valuable tool for drug discovery programs facing structural bottlenecks.